What is the main regulatory hurdle for Atripla in the European Union?

The main hurdle is a disagreement with the European Medicines Agency (EMEA) regarding the recommended method of Atripla administration, specifically whether it should be taken with or without food. Gilead is proposing administration on an empty stomach, while current European guidelines for Truvada (a component of Atripla) suggest taking it with food, and efavirenz (another component) on an empty stomach.

How could this EMEA issue impact Atripla's approval timeline?

The company is working to resolve this issue to maintain its target approval timeline for the end of 2007. However, if the EMEA requires additional clinical data or studies to address the administration method, it could lead to significant delays in the approval process.

What are the potential consequences if Gilead cannot resolve the administration issue with the EMEA?

If the EMEA requires extensive additional data or if the resolution is significantly delayed, Gilead may need to conduct further clinical trials. This could impact the feasibility of commercializing Atripla in the EU, potentially leading the company to cease efforts for EU sales or resulting in marketing approval with significant limitations on the product's use.

Is this issue unique to the European filing, and what is Gilead's basis for its proposed administration method?

Yes, this issue appears specific to the EU filing. Gilead's proposal to administer Atripla on an empty stomach is supported by data from two clinical studies and its post-marketing experience with Atripla in the United States.

GILD 8-K SEC Disclosure

Summary

Gilead Sciences, Inc. (GILD) filed an 8-K on July 20, 2007, to provide an update on its Marketing Authorisation Application (MAA) for Atripla™ (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in the European Union. The company is actively discussing a key issue with the European Medicines Agency (EMEA) regarding the administration of Atripla with or without food. This contrasts with the US prescribing information, where Truvada® (a component of Atripla) should be taken with food, but efavirenz should be taken on an empty stomach. Gilead proposes Atripla be taken on an empty stomach, supported by clinical data and US post-marketing experience. This regulatory discussion is critical as it directly impacts the anticipated approval timeline for Atripla in the EU, which Gilead had targeted for the end of 2007. Any requirement for additional data or significant delays from the EMEA could necessitate further clinical trials, potentially impacting the feasibility of commercialization and delaying or limiting the product's market entry. Investors should monitor developments closely as the company works to resolve this issue with the EMEA.

Key Highlights

1Gilead Sciences provided an update on the Atripla™ Marketing Authorisation Application (MAA) submission in the European Union.
2The primary issue under discussion with the European Medicines Agency (EMEA) concerns the administration of Atripla with or without food.
3Gilead proposes Atripla be administered on an empty stomach, citing clinical data and US post-marketing experience.
4This regulatory point is crucial as it could affect the projected approval timeline for Atripla in the EU, targeted for the end of 2007.
5The EMEA's decision could require additional clinical data, potentially leading to delays or necessitating further trials.
6Failure to resolve the issue or significant delays could impact Gilead's decision to commercialize Atripla in the EU or lead to limitations on its use if approved.

GILEAD SCIENCES, INC. 8-K Report, Corporate Update (Jul 20, 2007)

Summary

Key Highlights

Frequently Asked Questions